Latest news for Eden Research (OTC:EDNSF) Stock

Eden Research PLC is a UK-based company that develops and supplies biopesticide products and natural microencapsulation technologies to the crop protection, animal health, and consumer products industries. It operates through Agrochemical, Consumer products, and Animal health segments. It offers a range of product categories under Foliar Diseases Control, Soil Pest, Protected Glass House Crops, Vascular Diseases Control, and Post-Harvest Applications.

EDEN RESEACH PLC ORD by Eden Research plc.

Eden Research PLC

Last week, a U.S. Geological Survey (USGS) study found that nearly half the United States lies in potential landslide zones. The findings come from a newly released nationwide landslide susceptibility map, offering a county-by-county analysis of landslide risks nationwide.
The map, a product of advanced data analysis and high-resolution elevation data, shows that roughly 44% of U.S. territory could experience landslide activity. For millions of Americans, their homes and communities may be more vulnerable to destructive geological events than previously thought.
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
Benjamin Mirus, a research geologist with the USGS who worked on the project, said, &#8220;This new national landslide susceptibility map addresses an important but difficult question: which areas across the entire U.S. are prone to landslides?&#8221; The detailed assessment aims to support risk-reduction efforts and inform land-use planning in potentially unstable areas.
The map&#8217;s creation involved analyzing an inventory of nearly one million previous landslides, utilizing high-resolution national elevation data from the USGS 3D Elevation Program. The approach resulted in a far more detailed picture of landslide risk than was previously available, covering known high-risk areas and regions where landslide potential was poorly understood.
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
Certain regions stand out as particularly susceptible. Parts of Appalachia, including West Virginia and eastern Kentucky, show high landslide risks. The Rocky Mountains, California coast and southeast Alaska also prominently in the high-risk category. Over 90% of Puerto Rico is classified as having high landslide susceptibility.
The map&#8217;s release comes just after a sudden landslide in Ketchikan, Alaska, which resulted in one fatality and three injuries, according to the New York Times. <a href="https://www.benzinga.com/topic/climate-change">Climate change is worsening the risks</a> as heavy rainfall events – the primary trigger for landslides – are <a href="https://www.benzinga.com/markets/emerging-markets/23/12/36113247/wind-climate-change-and-the-future">becoming more frequent and intense due to global warming</a>. 
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
 The map offers insights into preparedness for homeowners and communities in high-risk areas and highlights regions where further landslide mapping and research are needed. The map presents a broad view of landslide susceptibility but does not predict specific events or their timing. Instead, it offers a probability-based assessment of areas more prone to landslides based on geological and topographical factors.
The USGS advises several precautionary measures for individuals residing in high-risk regions, including staying informed about local geology, monitoring warning signs like wall cracks and tilting trees, and maintaining an emergency plan. In certain situations, property owners may consider consulting engineering geologists for evaluations.
Read Next:
<ul>
<li>Mark Cuban believes &#8220;the next wave of revenue generation is around real estate and entertainment&#8221; —<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> this new real estate fund allows you to get started with just $100.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

Landslide Danger Looms For 44% Of U.S. Homes – Is Your Property In The Red Zone?

Advanced mobile assistant intended to amplify business operations and customer engagements powered by multi-modal AI workflows
CHARLOTTE, N.C., Sept. 23, 2024 /PRNewswire/ -- Honeywell&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) today announced that it is working to develop an artificial intelligence (AI)-enabled Multi-Modal Intelligent Agent for Honeywell mobile devices powered by Qualcomm Technologies, Inc. The agent will allow workers and customers in the distribution center and retail industries to interact naturally with their handheld devices through voice, pictures, and barcodes.
This AI-powered solution is built to function as a digital resource for the modern labor force and designed to enable today's stretched workforce to quickly tap into answers and outcomes, helping result in time savings, greater accuracy, and interactive results. The design and development of the Multi-Modal Intelligent Agent also supports Honeywell's alignment of its portfolio to three <a href="https://www.honeywell.com/us/en/press/2023/10/honeywell-to-realign-portfolio-to-three-powerful-megatrends-automation-future-of-aviation-and-energy-transition?utm_source=pressrelease&amp;utm_medium=pr&amp;utm_campaign=24-ess-am-ww-pr-701Hu000002MRT6IAO&amp;utm_content=prelease">compelling megatrends</a>, including automation.

News

QCOM

Honeywell To Develop AI-Enabled Agent Powered By Qualcomm

Biotech

General

ASMB

Assembly Biosciences Reports Interim Phase 1a Results From Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366; Says ABI-5366 Was Well Tolerated, Half-Life Of ~20 Days Supports Once-Weekly Or Once-Monthly Oral Dosing

Federal Reserve

Fed's Kashkari Said 50 Basis Point Fed Rate Cut Was Meaningful Step To Get Process Moving;  Expects Smaller Steps Going Forward For Fed

<ul>
<li>New TCT agreements contribute to supporting America's clean energy transition through tax credit transferability under the Inflation Reduction Act (IRA).</li>
<li>Projects are helping to pave the way for additional investments from the voluntary market to support developers fostering renewable energy projects.</li>
<li>Through strategic guidance from Schneider Electric, Kimberly-Clark will fund four new battery energy storage projects, demonstrating its support of critical grid resiliency.</li>
</ul>
BOSTON, Sept. 23, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=1845358604&amp;u=https%3A%2F%2Fwww.se.com%2Fus%2Fen%2F&amp;a=Schneider+Electric">Schneider Electric</a>,&nbsp;the global leader in the digital transformation of energy management and automation, today announced having facilitated several new TCT deals by <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=3439761111&amp;u=https%3A%2F%2Fwww.kimberly-clark.com%2Fen-us&amp;a=Kimberly-Clark">Kimberly-Clark</a> Corporation, one of the world's leading manufacturers of personal care and hygiene products and owner of household brands such as Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, and WypAll.
Since 2016, Schneider Electric has served as a strategic advisor to Kimberly-Clark in the manufacturer's ambitious decarbonization goals. These include a commitment to reduce absolute GHG emissions by 50% (1) by 2030 and progressing towards 100% renewable electricity in North America by 2030.
Most recently, Schneider Electric acted as a strategic advisor to Kimberly-Clark to help fund multiple battery energy storage projects as part of the rapid energy transition to green America's grid. These TCT deals represent one of the many approaches Kimberly-Clark is taking to advance sustainable solutions. The projects also serve as leading examples of how the voluntary market can support developers fostering key projects using the IRA's new tax credit transferability mechanism.
The work on these collective projects supports the advancement of battery energy storage in the Texas, USA, region, aligned with Kimberly-Clark's support of the green transition in renewable energy storage and generation. Kimberly-Clark's current vPPAs produce clean power from wind in Texas, which makes up <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=320883471&amp;u=https%3A%2F%2Fwww.epa.gov%2Fgreenpower%2Fgreen-power-partnership-national-top-100&amp;a=40%25+of+its+total+electricity+use+by+U.S.+operations+in+renewable+energy">40% of its total electricity use by U.S. operations in renewable energy</a> that Schneider Electric has advised on.
Details of the new Investment Tax Credit Transfer agreements include:
<ul>
<li>A $82.5M TCT agreement, a 180 MW battery energy storage facility</li>
<li>A $68M TCT agreement, a 100 MW battery energy storage facility</li>
<li>A $55M TCT agreement, a 100 MW battery energy storage project
<ul>
<li>A $32M TCT agreement, a 100MW battery energy storage facility</li>
</ul>
</li>
</ul>

Schneider Electric & Kimberly-Clark Announce Tax Credit Transfer Agreements To Advance Grid Resiliency

MBRX

Moleculin Biotech Presents Data On Annamycin At IASLC 2024, Showing Significant Tumor Growth Inhibition And Extended Survival In Lung Cancer Models With 100% Non-Cardiotoxicity

Morgan Stanley analyst Stephen Byrd maintains Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Overweight and raises the price target from $110 to $132.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Vistra, Raises Price Target to $132

Minneapolis Fed President Kashkari Said Labor Market Strong, Want To Keep It That Way; Won't Declare Mission Accomplished On Inflation

– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics (ASHG) 2024 Annual Meeting to be held November 5 – 9, 2024 in Denver, CO.

RLYB

Rallybio To Present Results Of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially And Ethnically Diverse Populations At The ASHG 2024 Annual Meeting

Management

GHSI

Guardion Health Sciences Announces Termination Of President And CEO Janet Hall, Effective Oct. 17

Nano Labs Announces Conversion Of $8.5M Interest-Free Loans From CEO And Vice Chairman Into Class A Ordinary Shares

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Small Cap Consumer Research raised the price target for JAKKS Pacific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) from $24 to $30. Small Cap Consumer Research analyst Eric Beder maintained a Buy rating. JAKKS Pacific shares fell 1% to close at $25.88 on Friday. <a href="https://www.benzinga.com/quote/JAKK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen increased the price target for CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) from $115 to $130. TD Cowen analyst Andrew Charles maintained a Buy rating. CAVA shares gained 2.9% to close at $128.79 on Friday. <a href="https://www.benzinga.com/quote/cava/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $300 to $345. Keybanc analyst Jackson Ader maintained an Overweight rating. CrowdStrike shares gained 8.1% to close at $299.85 on Friday. <a href="https://www.benzinga.com/quote/crwd/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $66 to $80. Deutsche Bank analyst Brian Bedell upgraded the stock from Hold to Buy. Bank of New York Mellon shares gained 0.1% to close at $71.82 on Friday. <a href="https://www.benzinga.com/quote/bk/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark raised Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) price target from $29 to $30. Benchmark analyst Daniel Kurnos maintained a Buy rating. Sinclair shares gained 4.3% to close at $14.67 on Friday. <a href="https://www.benzinga.com/quote/sbgi/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler boosted the price target for Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) from $184 to $200. Piper Sandler analyst Clarke Jeffries upgraded the stock from Neutral to Overweight. Wix.com fell 0.3% to close at $160.64 on Friday. <a href="https://www.benzinga.com/quote/wix/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird slashed Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) price target from $96 to $92. Baird analyst Colleen Kusy maintained an Outperform rating. Apellis Pharmaceuticals shares fell 11.5% to close at $32.51 on Friday. S<a href="https://www.benzinga.com/quote/apls/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from $74 to $94. Deutsche Bank analyst Bryan Keane maintained a Buy rating. PayPal shares fell 1% to close at $76.76 on Friday. S<a href="https://www.benzinga.com/quote/pypl/analyst-ratings">ee how other analysts view this stock.</a></li>
<li>Baird increased Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $186 to $200. Baird analyst David Koning maintained an Outperform rating. Fiserv shares fell 0.7% to close at $177.61 on Friday.<a href="https://www.benzinga.com/quote/FI/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Loop Capital slashed FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) price target from $317 to $288. Loop Capital analyst Rick Paterson maintained a Hold rating. FedEx shares dipped 15.2% to close at $254.64 on Friday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CRWD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23081011/image-177-1024x513.png" alt="" class="wp-image-560927" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23081011/image-177-1024x513.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23081011/image-177-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23081011/image-177-768x385.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/23081011/image-177.png 1347w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

APLS

CAVA

CRWD

JAKK

PYPL

SBGI

CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday

Offerings

Wayfair Announces $700M Senior Secured Notes Offering Due 2029, Proceeds To Be Used For Repayment Of Existing Convertible Notes And General Corporate Purposes

BDTX: 54% &#x7C; <a href="https://www.benzinga.com//node/40977620">Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.</a>
&nbsp;
VTYX: 42% &#x7C; <a href="https://www.benzinga.com//node/40978185">Ventyx Biosciences Announces Sanofi Has Agreed To Make A $27M Investment In Co. At An As-Converted Price Of $3.8243 Per Share, Pursuant To Which Sanofi Will Purchase 70,601 Shares Of Series A Non-Voting Convertible Preferred Stock</a>
&nbsp;
BHVN: 26% &#x7C; <a href="https://www.benzinga.com//node/40977584">Biohaven shares are trading higher after the company announced its study of Troriluzole for the treatment of spinocerebellar ataxia in achieved the primary endpoint.</a>

Movers

BDTX

BHVN

VTYX

Market-Moving News for September 23rd

SPRY

ARS Pharmaceuticals Announces Neffy Epinephrine Nasal Spray Now Available By Prescription Across U.S. Following FDA Approval For Treatment Of Type I Allergic Reactions, Including Anaphylaxis

Benchmark analyst Mike Hickey reiterates National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) with a Buy and maintains $8 price target.

Reiteration

NCMI

Benchmark Reiterates Buy on National CineMedia, Maintains $8 Price Target

Braskem's UTEC&#xAE; - Accelerating the Future of U.S. Lithium-Ion Battery Manufacturing
Braskem ((B3: BRKM3, BRKM5, and BRKM6, NYSE:<a href="https://www.benzinga.com/stock/BAK#NYSE">BAK</a>, LATIBEX: XBRK)), the Americas' leading polyolefins producer and a global pioneer in biopolymers, today proudly announces that the company has been selected by the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains to negotiate terms of a $50 million award under the Bipartisan Infrastructure Law. This landmark funding would expand Braskem's ultra-high molecular weight polyethylene (UHMWPE) production capabilities in La Porte, Texas, specifically targeting the lithium-ion battery separator (LIBS) market.

Contracts

Braskem Selected To Negotiate Terms Of A $50M Award From U.S. Department Of Energy To Drive Electrification Revolution

AIMD

Ainos To Initiate Taiwan Clinical Study Of VELDONA For Sjögren's Syndrome, Aims To Complete All Regulatory Approvals For The Study In Q4 Of 2024

Morgan Stanley analyst David Arcaro maintains Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Overweight and raises the price target from $233 to $313.

Morgan Stanley Maintains Overweight on Constellation Energy, Raises Price Target to $313

<ul>
<li>New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of Neuroblastoma &nbsp;</li>
<li>Study Illustrates Potential to Activate the Immune System Even in Cancers That Have Not Previously Responded to Checkpoint Inhibitors</li>
</ul>
CHICAGO and FORT WORTH, Texas, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the Scientific Reports publication of novel mechanistic data for its development candidate, elraglusib.
The article, entitled, "Targeted inhibition of glycogen synthase kinase‑3 using 9‑ING‑41 (elraglusib) enhances CD8 T‑cell‑reactivity against neuroblastoma cells" is <a href="https://www.globenewswire.com/Tracker?data=DGRVplC6ix3glbl_aeEgL-1ZeBgYfJ73t2Tc5sLbZLAD7Pwgv6IVqL2xvlQymYQN7OedaOt0JJEUYAB3aizc8f2obTVop-qVw3UQa85I2kCITZlhI8Dbz94vhhoX87Wj">available online.</a>

ACTU

Actuate Announces Scientific Reports Publication On Elraglusib's Novel Immunomodulatory Mechanism Of Action As A GSK-3β Inhibitor

iShares MSCI Denmark ETF declares semi-annual distribution of $0.3341

EDEN

EDNSF

Eden Research raises £9.9mln and secures first commercial Ecovelex order

Press Releases

Eden Research to Present at the Small Cap Virtual Investor Conference November 30, 2023

Eden Research

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Eden Research

News

Latest news for Eden Research (OTC:EDNSF) Stock